ArticleAntimicrobial agents and chemotherapy2019
Improved Methods for Assessing Therapeutic Potential of Antifungal Agents against Dermatophytes and Their Application in the Development of NP213, a Novel Onychomycosis Therapy Candidate.
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- An indole dimer antifungal metabolite from a rice seed endophyte inhibits ergosterol biosynthesis in fungal pathogens.Applied and environmental microbiology · 2026Article
- New and Investigational Treatment Options for Dermatomycosis in the Era of Antifungal Resistance.Journal of fungi (Basel, Switzerland) · 2026Review
- Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects.Acta pharmaceutica Sinica. B · 2025Review
- The Contribution of Human Antimicrobial Peptides to Fungi.International journal of molecular sciences · 2025Review
- In vivo toxicological evaluation of 3-benzylideneindolin-2-one: antifungal activity against clinical isolates of dermatophytes.BMC pharmacology & toxicology · 2025Article
- Host-Pathogen Interaction and Resistance Mechanisms in Dermatophytes.Pathogens (Basel, Switzerland) · 2024Review
- Alternate Antimicrobial Therapies and Their Companion Tests.Diagnostics (Basel, Switzerland) · 2023Review
- Antimicrobial and Anti-Inflammatory Activities of MAF-1-Derived Antimicrobial Peptide Mt6 and Its D-Enantiomer D-Mt6 against Acinetobacter baumannii by Targeting Cell Membranes and Lipopolysaccharide Interaction.Microbiology spectrum · 2022Article
- Novel and Investigational Treatments for Onychomycosis.Journal of fungi (Basel, Switzerland) · 2022Review
- Preliminary Characterization of NP339, a Novel Polyarginine Peptide with Broad Antifungal Activity.Antimicrobial agents and chemotherapy · 2021Article
- Formulation of Tioconazole andMolecules (Basel, Switzerland) · 2020Article
- NP213 (Novexatin®): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile.Medical mycology · 2020Article
- Antimicrobial host defence peptides: functions and clinical potential.Nature reviews. Drug discovery · 2020Review
- Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response.Frontiers in immunology · 2020Review
- Onychomycosis: An Updated Review.Recent patents on inflammation & allergy drug discovery · 2020Review
- Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy.Frontiers in cellular and infection microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Onychomycosis is a common, difficult-to-treat nail infection that is mainly caused by dermatophytes. Current therapies are not wholly effective and are associated with manifold side effects. The development of treatments for onychomycosis is challenging because standard
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.